RNU2-11P

Across TCGA pan-cancer cohorts, RNU2-11P RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of RNU2-11P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RNU2-11P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU2-11P is over-expressed in tumor.

KIRC, LUAD, and BRCA are the cancer types where RNU2-11P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU2-11P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	+0.955	<.001	12	view →
LUAD	All	All	+0.368	.001	6	view →
BRCA	All	All	+0.351	<.001	6	view →
CHOL	All	All	+2.016	<.001	5	view →
LUSC	All	All	+0.715	<.001	5	view →
LIHC	All	III,IV	+0.257	.005	5	view →
COAD	All	II,III,IV	+0.464	.006	4	view →
BLCA	All	III,IV	+0.644	.018	3	view →
KIRP	All	IV	+1.300	.020	2	view →
PRAD	All	All	+0.247	.017	2	view →
KICH	Female	II,III,IV	+0.545	.006	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

RNU2-11P–KIRC

Open the KIRC breakdown →